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Abstract: The memory-guided saccade task requires the remembrance of a peripheral target 10 
location, whilst inhibiting the urge to make a saccade ahead of an auditory cue. The literature has 11 
explored the endophenotypic deficits associated with differences in target laterality, but less is 12 
known about target amplitude. The data presented came from Crawford et al. (1995), employing a 13 
memory-guided saccade task among medicated and non-medicated patients with Schizophrenia 14 
(n=31, n=12), Bipolar Affective Disorder (n=12, n=17), and neurotypical controls (n=30). The current 15 
analyses explore the relationships between memory-guided saccades toward targets with different 16 
eccentricities (7.5o and 15o), the discernible behaviour exhibited amongst diagnostic groups, and 17 
cohorts distinguished based on symptomatology. Saccade gain control and final eye position were 18 
reduced among medicated-schizophrenia patients. These metrics were lessened further among 19 
targets with greater amplitudes (15o), indicating greater deficit. The medicated cohort exhibited 20 
reduced gain control and final eye positions in both amplitudes compared to the non-medicated 21 
cohort, with deficits markedly observed in the furthest targets. No group differences in 22 
symptomatology (positive and negative) were reported, however, greater deficit was observed 23 
toward the greatest amplitude. This suggests that within the memory-guided saccade paradigm, 24 
diagnostic classification is more prominent in characterising disparities in saccade performance 25 
than symptomatology. 26 
Keywords: Memory-Guided Saccades; Schizophrenia; Bipolar Disorder; Positive Symptoms; 27 
Negative Symptoms  28 
 29 
1. Introduction 30 
Research published over the past decade has highlighted and established an 31 
encouraging novel area of research which considers the oculomotor system as an effector 32 
system for visual memory [1, for review]. Research exploring the expression of memory 33 
through eye movements demonstrate how they are not simply a passive reflection of 34 
memory, but rather play an active role in contributing to the formation and retrieval of 35 
information [2]. 36 
 37 
The memory-guided saccade task is a highly informative paradigm, which requires 38 
remembering the location of a peripheral target, whilst inhibiting the urge to make a 39 
saccade to that target ahead of an auditory cue. Typically, individuals would produce a 40 
reflexive eye movement in response to a novel stimulus, but in the memory-guided 41 
saccade paradigm they are asked to suppress and delay their saccade until the 42 
presentation of a cue. Whilst suppressing this saccade, fixation should be maintained at 43 
the centre of the display while simultaneously encoding the spatial location of a 44 
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peripheral target stimulus. During the delay period before receiving the cue, cells in the 45 
superior colliculus respond to the continued presence of the fixation stimulus [3, 4], 46 
facilitating inhibition and maintaining the spatial representation of the peripheral 47 
location. Upon receiving the cue, a volitional saccade to the remembered target ensues. 48 
No visual information is provided on the location of the previously presented peripheral 49 
target at the moment of saccade initiation. This paradigm, therefore, examines the 50 
inhibition of a reflexive action, the ability to generate an internal representation of space 51 
(spatial working memory), and the inhibition of the saccadic motor program during the 52 
memorisation process. A major advantage of the oculomotor system is that detailed 53 
neurophysiological and biochemical operations can be explored using precise neuronal 54 
activity in equivalent or identical paradigms in animal studies. In seminal work, 55 
Goldman-Rakic and colleagues [5] demonstrated that D1 neurons in the dorsolateral pre- 56 
frontal cortex (DLPFC) played a critical role in memory-guided oculomotor controls, and 57 
the generation of representations in working memory. Research revealed that following 58 
inactivation of DLPFC with muscimol (a selective agonist for the GABAA receptors), 59 
memory-guided saccades become hypometric and inaccurate in a spatially specific 60 
manner [6]. While the DLPFC [5] and substantia nigra pars reticulata (SNpr) [7] are 61 
implicated in the short-term memory buffer utilised during the memory-guided saccade 62 
task, there is also thought that the parahippocampal cortex (PHC) may also be implicated 63 
in a varied version of the memory-guided saccade task. Research has shown that accuracy 64 
of memory-guided saccades, when memorisation delays are extended to between 1 and 65 
20 seconds, depends on the DLPFC [8], whilst the PHC is thought to be responsible for 66 
accuracy when the delays are longer than 20-seconds (and up to a few minutes). [8-11]. 67 
 68 
Saccadic eye movements are a ubiquitous form of information gathering 69 
(demonstrated in primates) [12,13] and play a role in modulating ongoing neural activity 70 
in the primate hippocampus [14-16]. However, Ryan et al. [1] highlight that there are no 71 
known direct connections between hippocampal subfields and the oculomotor system. 72 
Thus, they illustrated by examining whole-cortex connectivity in a model-based approach 73 
that there is an extensive set of polysynaptic pathways mediating the exchange of 74 
information between the oculomotor and memory systems [17]. Considering the 75 
functional dynamics and recurrent interactions of the network involved in the 76 
hippocampal guidance of ocular control, they highlight that neural activity in these areas, 77 
are important for the cognitive and motoric control of eye movements [18]. Moreover, 78 
electrophysiological studies in humans and primates [19, 20], highlight that hippocampal 79 
memory representations are used to guide saccades to behaviourally relevant locations 80 
[21]. With relevance to the present research, visual exploration of novel, but not repeated 81 
stimuli result in a reset of hippocampal theta oscillations [20], thus the consistency of this 82 
ability predicts the success of novel memory encoding [22]. Given the role of the prefrontal 83 
cortex and schizophrenia pathology and treatment, the memory-guided saccade task 84 
employed, with small memorisation periods and repeated stimulus presentation, would 85 
be expected to detect neurocognitive impairment in patients with schizophrenia. 86 
 87 
Previous research has explored the memory-guided saccade paradigm in relation to 88 
the psychosis-continuum, highlighting a series of deficits distinguishing patients from 89 
neurotypical controls [23, 24, for example]. In memory-guided saccades, schizophrenia 90 
patients have been shown to elicit increased latencies and/or reduced gain control and 91 
final eye positions [24-31] as well as elevated disinhibition errors [33]. Decreased gain 92 
control has been reported among psychosis patients and their relatives [14, 15, 20], as well 93 
as increased latencies [24, 27] among people with schizophrenia compared to controls. 94 
These deficits have been shown to predate the onset of the disease [27, 28]. This atypicality 95 
has been replicated in psychosis patients [23, 24, 27, 28, 34] independent of medication 96 
status [28], their full siblings [26], relatives [11, 30], and those with high-schizotypy [36- 97 
38]; supporting its candidacy as an oculomotor endophenotype.  98 




All research cited thus far has largely overlooked the potential role of spatial location. 100 
Given that targets closer to the fovea are more likely to capture attention due to the cortical 101 
magnification factor and increased salience. If near targets require greater levels of 102 
inhibition to avoid attentional capture, target eccentricity (how far away the remembered 103 
target is from central fixation) may be expected to be a highly relevant factor. This may 104 
also interact with symptomatology given that prefrontal impairment has been reliably 105 
associated in Schizophrenia (SZ) patients with predominantly negative symptoms [39-41]. 106 
There is evidence to suggest that differences may be observed when exploring these 107 
deficits in accordance with target eccentricity [42, 43]. Existing research has demonstrated 108 
deficits among patients with a family history of schizophrenia at smaller angles than 109 
patients without a family history of this disease [42]. It is therefore relevant to explore 110 
these deficits at different target eccentricities as this may provide higher specificity in 111 
detecting a marker of vulnerability in schizophrenia [26]. The current work explores the 112 
dataset reported by [23], to examine the effect target eccentricity (near vs far targets) has 113 
on performance in the memory-guided saccade task. 114 
 115 
There are very few studies investigating the influence of target eccentricity in the 116 
memory-guided saccade task, especially within psychosis patients. A key study, however, 117 
is reported by Landgraf et al. [26] who explored memory-guided saccade metrics among 118 
schizophrenia patients (n=16), their family members (n=19) and a control group (n=18). 119 
Data reported a reduction in errors from 46.2% at ‘small stimulus eccentricities’ (4o, 6o, 8o) to 120 
5.6% at ‘large stimulus eccentricities’ (10o, 12o) among controls. This finding suggests that 121 
controls are more susceptible to distractors that are closer to a central fixation point, 122 
however, among the schizophrenia patients and their family members, no difference in 123 
error production was reported. In alignment with the present research, Landgraf et al. [26] 124 
explored primary saccade gain control and final eye position metrics, where 125 
schizophrenia patients exhibited reduced performance when compared to their control 126 
counterparts but overlooked the potential mediating effect of target eccentricity. A 127 
conclusion of this study was that the memory-guided saccade paradigm provided a more 128 
specific way of identifying saccadic abnormalities than other saccade paradigms, with 129 
involuntary errors more prevalent in schizophrenia patients and their full-siblings, even 130 
at the largest target amplitudes. They concluded that the paradigm could be utilised in 131 
identifying saccadic abnormalities in psychoses. The present research therefore aims to 132 
expand on this analysis; investigating whether primary saccade gain control and final eye 133 
position metrics are affected by target eccentricity. 134 
 135 
The present research also incorporates both schizophrenia and bipolar disorder (BD) 136 
patients, to explore their comparative oculomotor responses to the memory-guided 137 
saccade task. There is very little research exploring memory-guided saccades among 138 
bipolar disorder patients. Crawford et al. [23, 44] illustrated no group differences 139 
(between schizophrenia, bipolar disorder, neurotics, and controls) in the latency metric, 140 
but trends towards significant reductions in gain control and final eye position among 141 
schizophrenia patients. In a systematic review, Carvalho et al. [45] did not report any 142 
literature exploring memory-guided saccades among individuals with Bipolar Disorder. 143 
Moreover, the schizophrenia cohort reported in the study carried out by Landgraf et al. 144 
[26] were all medicated; thus, the present manuscript will therefore explore memory- 145 
guided saccades among medicated and non-medicated individuals diagnosed with 146 
bipolar affective disorders, comparing their oculomotor behaviours with those exhibited 147 
by medicated and non-medicated individuals with schizophrenia. 148 
 149 
A distinct limitation of the Landgraf et al. [26] paper is the lack of reference to 150 
symptomatology. The symptomatology in the present research reflects on positive 151 
symptoms; which describe an excess or distortion of normal mental function (for example, 152 
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delusions, hallucinations, disorganized behaviour), and negative symptoms, which refer 153 
to a diminution or absence of normal mental or psychological functions related to 154 
motivation and interest (for example, anhedonia, asociality, and psychomotor poverty) or 155 
expression (for example, blunted affect [46]). Existing research has highlighted significant 156 
associations between patients with negative symptoms (as measured by either the SANS 157 
scale [47] or the PANSS [48]) and greater suppression errors in the antisaccade task [28, 158 
49-51]. In a small study (N=21) Winograd-Gurvich et al. [52] explored the influence of 159 
negative symptoms amongst a schizophrenia patient sample on a series of saccade tasks; 160 
one of which included a memory-guided task. They describe how the high-negative 161 
symptom group made a significantly greater percentage of errors than controls, with the 162 
memory-guided saccade paradigm producing significantly longer latencies than other 163 
saccade tasks, but there were no clear differences between the high and low negative were 164 
reported. No group differences were reported for gain control or final eye position 165 
measures; two metrics thought to be important in psychotic saccade deficits [53]. 166 
However, this study appears to be underpowered with only 10 and 11 participants per 167 
group. More recent research has highlighted the existence of different relationships 168 
between the symptoms of schizophrenia and saccade task performance. Obyedkov et al. 169 
[54] in a much larger study (N=156) highlighted that among schizophrenia patients and 170 
those at ultra-high risk for psychosis, the negative symptoms but not positive or 171 
disorganized symptoms were associated with atypical latencies in predictive and reflexive 172 
saccade tasks. This was replicated by Smith and Crawford [53] who found significant 173 
hypometria and lower gain control amongst those patients experiencing predominantly 174 
high-negative symptoms in a predictive saccade task. Based on the existing evidence 175 
showing greater deficit among those with predominantly negative traits, the current work 176 
explores whether this is true for the deficits observed in the memory-guided saccade task. 177 
To our knowledge this is the first study of the influence of symptomatology on the 178 
production of memory-guided saccades amongst schizophrenia and bipolar disorder 179 
patients. 180 
 181 
In this work we will address the extent to which target eccentricity influences latency, 182 
gain control, and final eye position measures in the memory-guided saccade task amongst 183 
schizophrenia and bipolar affective patients, as well as control participants. We also aim 184 
to address the influence medication may have on performance, and whether 185 
symptomatology can distinguish between typical saccadic behaviour and deficit. 186 
Answering these questions will further our understanding of essential features for the 187 
development of oculomotor biomarkers, which can be utilised in the early diagnosis of 188 
psychosis. 189 
 190 
2. Materials and Methods 191 
 2.1. Participant Selection 192 
The dataset presented in this research came from the Crawford et al. [23, 44] studies. 193 
The participant groups consisted of medicated schizophrenia patients (M-SZ; n=40; 21 194 
male and 19 female; mean age ± SD = 40 ± 12 years, range = 22-61 years), non-medicated 195 
schizophrenia patients (NM-SZ; n=18; 17 male and 1 female; mean age ± SD = 39 ± 13 years, 196 
range = 20-61 years), medicated bipolar affective disorder patients (M-BD; n=14; 7 male 197 
and 7 female; mean age ± SD = 44 ± 12 years, range = 20-60 years), non-medicated 198 
bipolar affective disorder patients (NM-BD; n=18; 12 male and 6 female; mean age ± SD = 199 
42 + 12 years, range = 20-60 years), and controls (CON; n=31; 16 male and 15 female; mean 200 
age ± SD = 39 ± 11 years, range = 25-57 years). All patients were identified from the case 201 
notes of out-patients at the Royal London Hospital and DSM-III-R criteria [55]. Controls 202 
were recruited from among all grades of hospital staff. Informed consent was obtained 203 
from all the participants and the study was approved by the Tower Hamlets Ethical 204 
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Committee. The CONs and their immediate families lacked any history of mental disease. 205 
Group matching, exclusion criteria, and further details of the recruitment procedures and 206 
clinical assessments are reported in supplementary materials (S1) and Crawford et al. [23, 207 
44]. Group means and standard deviations on all clinical measures collected in Table 1. A 208 
One-way ANOVA showed no difference in age between the diagnostic and control 209 
groups (F(4,118)=.546, p=.70). 210 
To address the symptomatology of the participant groups, The Scale for the 211 
Assessment of Negative Symptoms and the Scale for the Assessment of Positive 212 
Symptoms (SANS and SAPS) were employed. SANS measures negative symptoms on a 213 
25 item, 6-point scale [47]. Items are listed under five domains of affective blunting, alogia, 214 
avolition/apathy, anhedonia/asociality, and attention. SAPS measures positive symptoms 215 
on a 34 item, 6-point scale [48]. Items are listed under hallucinations, delusions, bizarre 216 
behavior, and positive formal thought disorder. 217 
Table 1. Clinical, psychiatric, and neuropsychological profile of Medicated (M) and Non- 218 
Medicated (NM) schizophrenic and bipolar patients, and control participants, as well as the 219 
current dosage of neuroleptic medication, expressed in chlorpromazine equivalent units (group 220 
means and standard deviation).  221 











1637 (572) - 1186 (474) - - 
Age (year) 39.9 (12.3) 39.4 (13.2) 43.6 (12.1) 42.1 (12.3) 38.5 (10.8) 
Disease 
duration (year) 
13.7 (10.7) 12.9 (14.8) 20.5 (11.6) 14.7 (13.6) - 
Age of onset 
(year) 








16.6 (21.7) 17.7 (17.8) 5.1 (9.2) 3.4 (6.6) 0.3 (0.2) 
2.2. Measurement of Saccades 222 
Apparatus set-up, procedure and the predictive saccade paradigm are reported in 223 
the supplementary materials (S1) and reported in Crawford et al. [23, 44].  224 
For this memory-guided saccade task, each trial began with an illuminated central 225 
LED. After 800 milliseconds (ms), a peripheral LED flashed on for 200ms. The central LED 226 
remained on, however, and the participant was instructed not to look towards the 227 
peripheral LED immediately. The central LED was extinguished 500 ms after offset of the 228 
peripheral target and, at this point, the participant was required to make a saccade to the 229 
remembered location of the previously illuminated peripheral LED. In this paradigm, the 230 
buzzer onset that provided the temporal cue, was coincident with the offset of the central 231 
(fixation) LED. (see Figure 1 for schematic representation of this paradigm). 232 
 233 
2.3. Data Processing and Statistical Analysis. 234 
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In the memory-guided saccade paradigm, the latency and spatial accuracy or gain 235 
(i.e. saccade eccentricity/target eccentricity) of the initial saccade and the gain of the final 236 
eye position (FEP) on each trial was analysed. The mean and standard deviation of each 237 
parameter was calculated for the four target locations. In the current paradigms, the 238 
number of trials on which a failure of saccadic suppression occurred was tallied for each 239 
participant. In calculating latency and gain, these erroneous responses were discarded. In 240 
assessing saccadic distractibility, an error was registered if a saccade occurred during the 241 
500ms delay between target offset and the imperative cue, buzzer onset (accompanied by 242 
fixation LED offset). For the target eccentricity analyses, the ‘Near’ targets were classified 243 
as those at ±7.5o and the ‘Far’ targets were classified as those at ±15o. ±7.5o and ±15o were 244 
chosen to address previous studies which have used smaller target amplitude (e.g. 245 
2o)separations which are ambiguous in whether they are classified as ‘near’ or ‘far’. 246 
Figure 1. Saccadic target paradigm for the memory-guided saccade task. Note: The targets were 247 
only visible when lit up. See Supplementary Materials for full description of the target 248 
configuration and the subject instructions.  249 
3. Results 250 
3.1. Diagnosis-based Analysis 251 
For the diagnostic-based analyses, participants were separated into M-SZ (n=29), NM-SZ 252 
(n=11), M-BD (n=12), NM-BD (n=17), and CON (n=30). To explore the effect of 253 
neuroleptic medication on performance in the memory-guided saccade task, diagnostic 254 
groups (SZ and BD) were collapsed into whether they were neuroleptic medicated 255 
(n=41) or not on neuroleptic medication (n=68). 256 




Figure 2. A comparison of performance in the (a) Gain and (c) Final Eye Position 258 
measures between the two target eccentricities within each diagnostic group; A 259 
comparison of performance in the (b) Gain and (d) Final Eye Position measures between 260 
the two peripheries between the medicated and non-medicated cohorts (collapsed across 261 
diagnostic category). For reference, the Control cohort are included here but were not 262 
included in the reported analysis. * refers to significance at the p<.05 level. ** refers to 263 
significance at the p<.01 level. Error bars refer to Standard Error.  264 
 265 
3.1.1. Saccade Primary Saccade Gain 266 
A 2 (Target eccentricity: Far, Near) x 5 (Group: M-SZ, NM-SZ, M-BD, NM-BD, CON) 267 
repeated-measures ANOVA was carried out on the primary saccade gain data with 268 
Bonferroni Post Hoc Tests for multiple comparisons, where a main effect of target 269 
eccentricity (F(1,93)=8.905, p=.004, ηp2=.087) and group (F(4,93)=4.920, p<.001, ηp2=.175) 270 
were found (see Figure 2(a)). Bonferroni post hoc analyses for multiple comparisons 271 
illustrated how these distinctions were driven by differences between the M-SZ vs CON 272 
(p<.001) and M-SZ vs NM-BD (p=.019) groups (see Figure 2(a)). Gain control in the M-SZ 273 
group was therefore significantly reduced when contrasted with the NM-BD and CON 274 
groups. To explore the effect of neuroleptic medication, a 2 (Target eccentricity: Far, 275 
Near) x 2 (Medication Status: M, NM) repeated-measures ANOVA was executed, where 276 
** 
* 
(c)                                      (d) 
(a)                                        (b) 
* 
Near vs Far ** 
*
* 
Near vs Far ** 
*
* 
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a main effect of target eccentricity (F(1,106)=13.979, p<.001, ηp2 =.117) and medication 277 
status (F(1,106)=16.181, p<.001, ηp2=.132) was found. This relationship suggests that the 278 
medicated cohort produced significantly lower gain data in both eccentricities compared 279 
to the non-medicated cohort (see Figure 2(b)). 280 
 281 
3.1.2. Saccade Final Eye Position 282 
A 2 (Target eccentricity: Far, Near) x 5 (Group: M-SZ, NM-SZ, M-BD, NM-BD, CON) 283 
repeated-measures ANOVA was performed on the FEP data, where a main effect of 284 
target eccentricity (F(1,93)=9.253, p=.003, ηp2=.090) and group (F(4,93)=3.065, p=.020, 285 
ηp2=.116) were found. Bonferroni Post Hoc analyses for multiple comparisons illustrated 286 
how these distinctions were driven by differences between the M-SZ and NM-BD 287 
(p=.033) groups (see Figure 2(c). FEP in the M-SZ group was therefore significantly 288 
reduced when contrasted with the NM-BD group. To explore the effect of neuroleptic 289 
medication, a 2 (Target eccentricity: Far, Near) x 2 (Medication Status: M, NM) repeated- 290 
measures ANOVA was carried out. A main effect of target eccentricity (F(1,106)=16.345, 291 
p<.001, ηp2=.134) and medication status (F(1,106)=10.677, p<.001, ηp2=.092) was observed. 292 
This relationship suggests that the medicated cohort displayed greater hypometria in 293 
both eccentricities compared to the non-medicated cohort (see Figure 2(d)). A Target 294 
eccentricity*medication status interaction was also found (F(1,106)=3.858, p=.05, 295 
ηp2=.035). 296 
 297 
3.1.3. Saccade Latency 298 
A 2 (Target eccentricity: Far, Near) x 5 (Group: M-SZ, NM-SZ, M-BD, NM-BD, CON) 299 
repeated-measures ANOVA was carried out, where no significant main effects were 300 
observed. To explore the effect of neuroleptic medication, a 2 (Target eccentricity: Far, 301 
Near) x 2 (Medication Status: M, NM) repeated-measures ANOVA was executed on the 302 
data. No significant main effects or interactions were observed. This is consistent with 303 
previous research [10, 26] revealing that saccade parameter of primary saccade latency is 304 
relatively insensitive to psychosis, neuroleptic or target eccentricity. 305 
 306 
In sum, no effects of target eccentricity were observed for the latency metric. This is 307 
analogous with the existing literature [10, 38]. Landgraf and colleagues [26] highlighted 308 
an overall group difference in gain control and final eye position; whereby the SZ 309 
patients showed reduced abilities when compared to their family members and controls. 310 
The present research mimics this notion, but develops the idea further. Consequently, 311 
gain control and final eye position in the M-SZ patients was significantly diminished in 312 
contrast to the NM-BD and CON groups. Moreover, these measures were lessened 313 
further among targets with greater eccentricities (15o). This finding was paralleled again 314 
when investigating the effect of neuroleptic medication: expectedly, the medicated 315 
cohort (regardless of diagnosis) exhibited reduced gain control and final eye positions in 316 
both eccentricities compared to the non-medicated cohort, but this deficit is markedly 317 
observed in the furthest targets. 318 
3.2. Symptoms-based Analysis (1) 319 
To establish that collapsing near and far targets from both the left and right literalities 320 
would not add any uncertainties to the data, a 2 (Laterality: Left, Right) x2 (Group: high- 321 
SANS, low-SANS) repeated measures ANOVA was explored; illustrating no significant 322 
effects for latency, gain or FEP in either laterality (p>0.5). Thus, the analyses include 323 
‘Near’ targets (those at ±7.5o) and ‘Far’ targets (±15o). 324 
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For the symptom-based analyses, a median split was used to divide the participants into 325 
a high- (score>18) and low- (score<18) negative/positive symptoms group. Initially, 326 
groups with high-/low- negative symptoms or high-/low- positive symptoms were 327 
collapsed across diagnosis to explore the singular influence of positive and negative 328 
symptomatology (regardless of diagnostic classification) on memory-guided saccade 329 
performance. The constitution of the cohort were as follows: high-SANS (n=24), low- 330 
SANS (n=39), high-SAPS (n=37) and low-SAPS (n=27). 331 
Figure 3. A comparison of performance in the (a) Gain and (b) Final Eye Position 332 
measures between the two target eccentricities based on their negative and positive 333 
symptoms. For reference the Control cohort are included here but were not included in 334 
the reported analysis. ** refers to significance at the p<.01 level. Error bars refer to 335 
Standard Error. 336 
 337 
3.2.1. Primary Saccade Gain 338 
A 2 (Target eccentricity: Far, Near) x 2 (Group: high-SANS, low-SANS) repeated 339 
measures ANOVA was carried out. This analysis highlighted a main effect of target 340 
eccentricity (F(1,61)=7.766, p=.007, ηp2=.113; Figure 3(a)). When looking at the descriptive 341 
statistics, it appears that differences between high- and low-SANS groups are more 342 
apparent for the furthest target, but no significant group effect was found. To explore 343 
this potential relationship a multiple regression was performed to predict group 344 
membership (high vs low negative groups, collapsed across diagnostic label) from gain 345 
control towards the furthest target and gain control towards the nearest target. These 346 
variables did not significantly predict group membership (F(2,60)=1.41, p=.252, R2=.045). 347 
A 2 (Target eccentricity: Far, Near) x 2 (Group: high-SAPS, low-SAPS) repeated 348 
measures ANOVA was also carried out; displaying a main effect of target eccentricity 349 
also (F(1,62)=7.412, p=.008, ηp2=.107; Figure 3(b)). For both analyses, gain control 350 
displayed greater reductions towards the furthest target eccentricity. No group 351 
differences were observed for either analysis. A multiple regression was performed to 352 
predict group membership (high vs low positive groups, collapsed across diagnostic 353 
label) from gain control towards the furthest target and gain control towards the nearest 354 
target. These variables did not significantly predict group membership (F(2,61)=.274, 355 
p=.76, R2=.009). 356 
 357 
3.2.2. Saccade Final Eye Position 358 
(a)                                        (b) 
Near vs Far ** Near vs Far ** 
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A 2 (Target eccentricity: Far, Near) x 2 (Group: high-SANS, low-SANS) repeated 359 
measures ANOVA was carried out. The data reports a main effect of target eccentricity 360 
in FEP (F(1,61)=11.192, p<.001, ηp2=.155; Figure 3(c)), whereby more variability is 361 
observed in the furthest target. To explore this idea, a multiple regression was 362 
performed to predict group membership (high vs low negative groups, collapsed across 363 
diagnostic label) from FEP towards the furthest target and FEP towards the nearest 364 
target. These variables did not significantly predict group membership (F(2,60)=1.66, 365 
p=.199, R2=.052). A 2 (Target eccentricity: Far, Near) x 2 (Group: high-SAPS, low-SAPS) 366 
repeated measures ANOVA was also executed for the high-/low- SAPS groups; showing 367 
a main effect of target eccentricity in FEP (F(1,62)=10.048, p=.002, ηp2=.139; Figure 3(d)). 368 
For both analyses, FEP showed larger reductions towards the furthest most target. No 369 
group differences were observed for either analysis. A multiple regression was 370 
performed to predict group membership (high vs low positive groups, collapsed across 371 
diagnostic label) from FEP towards the furthest target and FEP towards the nearest 372 
target. These variables did not significantly predict group membership (F(2,61)=.103, 373 
p=.902, R2=.003). 374 
 375 
3.2.3. Saccade Latency 376 
A 2 (Target eccentricity: Far, Near) x 2 (Group: high-SANS, low-SANS) repeated 377 
measures ANOVA was performed; showing no significant effect of the latency metric. 378 
The same analysis (a 2 (Target eccentricity: Far, Near) x 2 (Group: high-SAPS, low-SAPS) 379 
repeated measures ANOVA) was carried out for the high- and low-SAPS groups, 380 
displaying the same result. 381 
3.2. Symptoms-based Analysis (2) 382 
To investigate the effect of symptomatology between diagnostic categories, a similar 383 
analysis was repeated. Here, participants were grouped based on their high- /low- 384 
positive/negative symptom scores and were then divided by diagnostic category: high- 385 
SANS (SZ n= 13; BD n= 11), low-SANS (SZ n= 11; BD n= 28), high-SAPS (SZ n= 20; BD n= 386 
17), low-SAPS (SZ n= 11; BD n= 16). 387 
 388 
3.2.1. Primary Saccade Gain 389 
A 2 (Target eccentricity: Far, Near) x 4 (Group: SZ high-SANS, SZ low-SANS, BD high- 390 
SANS, BD low-SANS) repeated measures ANOVA was performed. A significant effect 391 
of target eccentricity was found in the gain metric (F(1,59)=7.51, p=.008, ηp2=.11; Figure 392 
4(a)); suggesting reduced gain control for the furthest targets. To explore this potential 393 
relationship a multiple regression was performed to predict group membership (high vs 394 
low negative groups, divided by diagnostic label) from gain control towards the furthest 395 
target and gain control towards the nearest target. These variables statistically 396 
significantly predicted group membership (F(2,60)=4.65, p<.01, R2=.134). Only gain 397 
control towards the furthest target added statistically significantly to the prediction, 398 
p=.006. The equivalent repeated-measures ANOVA was carried out for the SAPS 399 
groups; illustrating a significant effect of target eccentricity (F(1,60)=8.29, p=.006, ηp2=.12; 400 
Figure 4(b)). No group differences were observed for either analysis. A multiple 401 
regression was performed to predict group membership (high vs low positive groups, 402 
divided by diagnostic label) from gain control towards the furthest target and gain 403 
control towards the nearest target. These variables statistically significantly predicted 404 
group membership (F(2,61)=3.09, p=.05, R2=.092). Only gain control towards the furthest 405 
target added statistically significantly to the prediction, p=.02. 406 
 407 
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Figure 4. A comparison of performance in the (a) Gain and (b) Final Eye Position 408 
measures between the two extremities within each diagnostic group based on their 409 
negative and positive symptoms. For reference the Control cohort are included here but 410 
were not included in the reported analysis. Error bars refer to Standard Error.  411 
 412 
3.2.2. Saccade Final Eye Position 413 
A 2 (Target eccentricity: Far, Near) x 2 (Group: high-SANS, low-SANS) repeated A 2 414 
(Target eccentricity: Far, Near) x 4 (Group: SZ high-SANS, SZ low-SANS, BD high- 415 
SANS, BD low-SANS) repeated measures ANOVA was carried out. A significant effect 416 
of target eccentricity was found in the FEP (F(1,59)=10.72, p=.002, ηp2=.15) metric (Figure 417 
4(c)); suggesting greater undershooting for the furthest targets. To explore this target 418 
eccentricity relationship further, a multiple regression was performed to predict group 419 
membership (high vs low negative groups, divided by diagnostic label) from FEP 420 
towards the furthest target and FEP towards the nearest target. These variables 421 
statistically significantly predicted group membership (F(2,60)=4.06, p=.02, R2=.119). 422 
Only FEP towards the furthest target added statistically significantly to the prediction, 423 
p=.007. The equivalent repeated-measures ANOVA analysis was executed for the SAPS 424 
groups; illustrating a significant effect of target eccentricity (F(1,60)=7.89, p=.007, 425 
ηp2=.116; Figure 4(d)). No group differences were observed for either analysis. A 426 
multiple regression was performed to predict group membership (high vs low positive 427 
groups, divided by diagnostic label) from FEP towards the furthest target and FEP 428 
(c)                                        (d) 
Near vs Far ** Near vs Far ** 
Near vs Far ** 
Near vs Far ** 
(a)                                        (b) 
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towards the nearest target. These variables did not statistically significantly predict 429 
group membership (F(2,61)=2.86, p=.06, R2=.086). Only FEP towards the furthest target 430 
added statistically significantly to the prediction, p=.026. 431 
 432 
3.2.3. Saccade Latency 433 
A 2 (Target eccentricity: Far, Near) x 4 (Group: SZ high-SANS, SZ low-SANS, BD high- 434 
SANS, BD low-SANS) repeated measures ANOVA was carried out; showing no 435 
significant effect of the latency metric. The equivalent analysis was carried out for the 436 
SAPS groups, illustrating no main effects. 437 
Figure 5. A comparison of performance in the (a) Gain and (b) Final Eye Position 438 
measures between the two target eccentricities and the high-/low- SANS/SAPS groups 439 
(regardless of diagnostic category). For reference the Control cohort are included here 440 
but were not included in the reported analysis. * refers to significance at the p<.05 level. 441 
Error bars refer to Standard Error. 442 
3.3. Neuroleptic Medication on Symptomalogy 443 
To explore the effect of neuroleptic medication on symptomatology – when 444 
collapsed across diagnostic category – a 2 (Target eccentricity: Far, Near) x 4 (Group: 445 
Medicated high-SANS, Medicated low-SANS, Non-Medicated high-SANS, Non- 446 
Medicated low-SANS) repeated measures ANOVA was executed and highlighted no 447 
significant differences in the latency metric, but a main effect of target eccentricity in both 448 
the gain (F(1,59)=4.686, p=.034, ηp2=.074) and FEP (F(1,59)=6.201, p=.016, ηp2=.095) 449 
measures (see Figure 5(a)). A 2 (Target eccentricity: Far, Near) x 4 (Group: Medicated 450 
high-SAPS, Medicated low-SAPS, Non- Medicated high-SAPS, Non- Medicated low- 451 
SAPS) repeated measures ANOVA highlighted no significant differences in the latency 452 
metric, but a main effect of target eccentricity in both the gain (F(1,60)=6.700, p=.012, 453 
ηp2=.100) and FEP (F(1,60)=9.341, p=.003, ηp2=.135) measures (see Figure 5(a)). 454 
(a)                                        (b) 
Near vs Far * Near vs Far * 
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In sum, no symptom-based group or target eccentricity differences were observed 455 
in relation to the latency metric. This aligns with the data reported in the diagnosis- 456 
based analysis. Across analyses exploring the gain control and final eye position metric 457 
no group differences were observed. This highlights a divergence from prior literature 458 
reporting greater deficit among individuals with more negative symptoms in the 459 
memory-guided saccade task [52]. Winograd-Gurvich et al. [52] reported these effects 460 
among percentage of errors; thus, gain control illustrates a distinctly different story. 461 
Throughout the reported symptom-based analyses, however, greater deficit is observed 462 
toward the target with the greatest eccentricity. The analysis investigating the influence 463 
of neuroleptic medication illustrated a clear distinction in gain control and final eye 464 
position data between target eccentricities: with greater hypometric performance 465 
observed toward the furthest eccentricity. 466 
Figure 6. A comparison of error production across the memory-guided saccade 467 
paradigm in (a) diagnostic groups divided by symptomatology, and (b) symptom 468 
groups (regardless of diagnostic criteria). For reference, the Control cohort are included 469 
here but were not included in the reported analysis. * refers to significance at the p<.05 470 
level. Error bars refer to Standard Error.  471 
3.4. Symptomalogy on Error Rates 472 
Crawford et al. [23, 44] reported significantly more errors were exhibited by the 473 
schizophrenia patients when compared to bipolar affective disorder patients and control 474 
participants. Furthermore, Winograd-Gurvich et al. [52] described how a high-negative 475 
symptom group made a significantly greater percentage of errors than controls. Thus, to 476 
explore the influence of symptomatology on error rate production, groups were 477 
collapsed into high-SANS (n=36) and low-SANS (n=38) categories, regardless of 478 
diagnostic category. This was also true for high-SAPS (n=37) and low-SAPS (n=38). 479 
When investigated in this manner the high-SANS group were shown to produce 480 
significantly more errors than the low-SANS (F(1,72)=4.93, p=.03), but this was not true 481 
of the high-/low- SAPS groups (F(1,73)=.55, p=.46; Figure 6(b)). See the Supplementary 482 
Materials (S2) for all descriptive statistics. This provides support for previous literature 483 
[52, 53], fostering further the notion that psychotic saccadic deficits may be driven by 484 
those individuals experiencing predominantly negative symptoms.  485 
As per the symptom-based analyses reported beforehand, the diagnostic groups were 486 
also divided using a median-split into those with high and low negative/positive 487 
symptoms: SZ high-SANS (n=17), SZ low-SANS (n=12), BD high-SANS (n=14), BD low- 488 
SANS (n=31), SZ high-SAPS (n=26), SZ low-SAPS (n=19), BD high-SAPS (n=8), BD low- 489 




(a)                                        (b) 
* 
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between the groups (F(3,70)=3.13, p=.03; Figure 6(a)), whereby significantly more errors 491 
were produced by the SZ high-SANS cohort compared to the BD low-SANS cohort 492 
(p=.03). No significant differences were found for the same analysis with high- and low- 493 
SAPS (F(3,71)=2.27, p=.09).  494 
4. Discussion 495 
To our knowledge this is the first study of memory-guided saccades to explore target 496 
eccentricity in relation to psychosis diagnosis, psychotic symptomatology and the effect 497 
of medication. In a recent paper, greater errors were produced by SZ patients [43] in 498 
response to further targets (12o), when compared to near target (6o), although no 499 
exploration was given toward the breakdown of symptomatology in this patient group. 500 
The present research therefore expanded this finding to explore the effect of target 501 
eccentricity across diagnostic groups, and between symptom-types. The importance of 502 
eccentricity in saccade paradigms relates to the mammalian cortical magnification factor. 503 
The representation of retinal ganglion cells is disproportionately increased for foveal 504 
compared to peripheral retinal cells & proportional to the distance from the foveal region. 505 
Thus, the projections and resolution from 15o will be substantially reduced compared to 506 
7.5o. Therefore, 15o activation is likely to be generate a weaker cortical representation and 507 
therefore potentially more vulnerability to the psychopathology of psychosis. Moreover, 508 
larger saccades require greater energy expenditure, with larger neural pulse-steps to 509 
generate increased peak velocity and saccade duration for larger saccades. This increased 510 
energy demand may make larger saccades, and in the context of the present research, 511 
memory representation, more vulnerable to psychopathology. 512 
 513 
The current analyses focused on two questions, 1) how do psychotic disorders 514 
(schizophrenia and bipolar affective disorder) respond when presented with targets of 515 
differing eccentricity in the memory-guided saccade task, and how does medication 516 
influence this performance, and 2) how do patients experiencing predominantly negative 517 
or predominantly positive symptoms perform? 518 
 519 
Data demonstrated no significant group differences when utilising the latency 520 
metric; replicating the existing research carried out by Schwartz et al. [42] and Landgraf 521 
et al. [26]. With regards to gain control and final eye position, group differences became 522 
apparent, highlighting greater deficit among medicated schizophrenia patients and a 523 
generally larger impairment towards the furthest target. This finding contrasts the 524 
existing literature, whereby deficits in gain control were reported to be prominent among 525 
patients with a family history of schizophrenia at smaller angles [42]. However, Schwartz 526 
and colleagues found reduced gain at smaller angles (5o–10o) in those patients with a 527 
family history of schizophrenia, whereas, at larger angles (16o-30o) both patients with and 528 
without a family history of schizophrenia exhibited reduced gain control compared to 529 
controls. Thus, the present research is consistent with the relationship shown by Schwartz 530 
et al. [42] at the far targets. This is also supported by a recent study by Norouzi et al. [43] 531 
who highlighted, among a neurotypical sample, that greater quantities of errors are made 532 
toward a target with a greater eccentricity (12o). 533 
 534 
Similarly, in relation to symptomatology, greater hypometria and reduced gain 535 
control was observed toward the furthest targets. Throughout the symptom-based 536 
analyses greater deficit is observed toward the target with the greatest eccentricity; 537 
although, although no group differences were reported throughout the symptom-based 538 
analyses. To explore the idea that the far target may be the better predictor of deficit 539 
among these participant groups, multiple regressions showed that when exploring 540 
symptomatology (divided by diagnostic category, i.e. SZ high-SANS vs BD high SANS), 541 
only the furthest targets significantly accounted for unique group variance in both the 542 
eccentricity gain and FEP measures. This, however, was only true when diagnostic 543 
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category was used to divide the symptom-based groups. When high-/low- SANS groups 544 
were collapsed across diagnoses, these significant predictions withdrew. The analysis 545 
investigating the influence of medication illustrated a clear distinction in gain control and 546 
final eye position data between target eccentricities: with greater hypometric performance 547 
observed toward the furthest eccentricity and greater deficit for those medicated patients.  548
 549 
In addition to the saccade metrics reported, the present research also explored error 550 
production between groups and symptomatology. A series of studies [52-54] reported that 551 
greater saccade deficit was observed among individuals who presented with 552 
predominantly negative symptoms. Specifically, a greater proportion of errors have been 553 
reported among those with high-negative symptoms [52]; prompting the investigation of 554 
error production among the current patient cohort. When symptomatology was explored 555 
by collapsing all diagnostic categories into predominantly high/low negative/positive 556 
symptoms, the high-SANS group were shown to produce significantly more errors than 557 
the low-SANS, supporting existing hypotheses. Further, when symptomatology was 558 
explored considering diagnostic criteria as well, significantly more errors were produced 559 
by the SZ high-SANS cohort and the BD high-SANS cohort in comparison to their 560 
corresponding low-SANS cohorts. No such relationship was found for the comparative 561 
positive symptoms. This strengthens the notion that saccade deficits, on this occasion, 562 
error production, are driven by negative symptoms. 563 
4.1. Strengths and Limitations 564 
The present research aimed to provide an update on the existing understanding of 565 
the memory-guided saccade paradigm, taking into account the methodological 566 
limitations in the previous literature. To extend our understanding of memory-guided 567 
saccade performance among psychosis patients, we included three measures of 568 
oculomotor abilities – latency, gain control, and final eye position – to provide a more 569 
comprehensive insight into the relationship of psychotic symptoms and target 570 
eccentricity. The present data supports the view that gain control and final eye position 571 
are promising predictors of psychosis severity; a notion supported by the lack of main 572 
effects observed for the latency measure throughout analyses. Moreover, the present 573 
data also argues that when investigating degree of deficit among psychosis-spectrum 574 
diagnoses, the inclusion of distance target eccentricities (at least 15o) is important, and 575 
that reliance on near target eccentricities will risk a loss in sensitivity. Indeed, when 576 
resources are limited, it will be a more efficient approach to include only the furthest 577 
targets as they provide a sensitive predictor of clinical impairment. 578 
All of the schizophrenia patients who partook in the research reported by Schwartz 579 
et al. [42] and Landgraf et al. [26] were medicated; thus, we sought to explore whether 580 
differences in memory-guided saccade performance would occur as a consequence of 581 
neuroleptic medication status. The data revealed that the medicated groups (with 582 
reference to both diagnostic classification and symptomatology-based analyses) 583 
performed with heightened deficit in both gain control and final eye position metrics. 584 
This, as far as we are aware, is the only research to explore the influence of medication 585 
on memory-guided saccade performance in relation to target eccentricity. Moreover, to 586 
extend the investigation reported by Winograd-Gurvich et al. [52], the current research 587 
also explored the effect of target eccentricity on symptomatology. Winograd-Gurvich et 588 
al. [52] reported (with reference to target laterality) that among a cohort of medicated 589 
schizophrenia patients, divided by their experience of negative symptoms (high vs low), 590 
no group differences were reported for gain control or final eye position when 591 
comparing the high vs low symptom groups with controls. This finding was replicated 592 
in the present dataset with reference to target eccentricity: no group difference with 593 
respect to symptomatology were reported. This suggests that within the memory-guided 594 
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saccade paradigm, diagnostic classification is more prominent in distinguishing 595 
differences in saccade performance than symptomatology. 596 
As well as strengths to the present research, there are also limitations worth noting 597 
so they can be addressed when moving forward into future memory-guided saccade 598 
explorations. Landgraf et al. [26] reported a reduction in error production between small 599 
eccentricities and larger eccentricities, which was not present among patients; the 600 
present research displayed analyses exploring overall error production amongst 601 
symptom-groups, but dividing the errors between target eccentricities was an analysis 602 
we weren’t able to explore in relation to symptomatology. As the present research relied 603 
on secondary data analyses it was not possible to explore errors produced toward near 604 
and far targets, but this should be considered a priori in future work. Another constraint 605 
on the present research were the differential sized cohorts; the absence of a sample size 606 
calculation for the different groups used throughout the series of hypothesis-driven 607 
analyses, makes the evaluation of statistical power adequacy difficult. This was 608 
highlighted particularly during the symptom-based analyses, where we explored 609 
symptomatology – predominantly high- / low-SANS and high- / low-SAPS – within the 610 
diagnostic classifications. To combat the cohort imbalance, we reported the above 611 
analyses and also collapsed high SANS and low SANS groups across diagnosis to 612 
explore the singular influence of positive and negative symptomatology (regardless of 613 
diagnostic classification). 614 
5. Conclusions 615 
The present research extends our understanding of deficit displayed in the memory- 616 
guided saccade task and the influence target eccentricity has on psychotic performance. 617 
This study reveals that a greater target eccentricity discriminates better between 618 
psychiatric groups, particularly for gain control and final eye position metrics. Extensive 619 
research in the last 20 years has substantially advanced our understanding of the essential 620 
features for the development of oculomotor biomarkers required for the early diagnosis 621 
of psychosis. The current findings build on this work by revealing the importance detailed 622 
parameter measurement to optimize the sensitivity of these paradigms.   623 
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